December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Antiphospholipid Syndrome Diagnosed by Ocular Vascular Occlusion as the First Clinical Manifestation: Report of Three Cases
Author Affiliations & Notes
  • CE Araya-Munoz
    Retina APEC Mexico Mexico
  • G Lopezcarasa-Hernandez
    Retina APEC Mexico Mexico
  • RM Romero-Castro
    Retina APEC Mexico Mexico
  • C Amigo
    Instituto Nacional de Ciencias Medicas y Nutrición Mexico Mexico
  • JM Jimenez-Sierra
    Retina APEC Mexico Mexico
  • Footnotes
    Commercial Relationships   C.E. Araya-Munoz, None; G. Lopezcarasa-Hernandez, None; R.M. Romero-Castro, None; C. Amigo, None; J.M. Jimenez-Sierra, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 499. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      CE Araya-Munoz, G Lopezcarasa-Hernandez, RM Romero-Castro, C Amigo, JM Jimenez-Sierra; Antiphospholipid Syndrome Diagnosed by Ocular Vascular Occlusion as the First Clinical Manifestation: Report of Three Cases . Invest. Ophthalmol. Vis. Sci. 2002;43(13):499.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To describe ocular vascular occlusion as the first manifestation of antiphospholipid syndrome. Antiphospholipid Syndrome (APS) is an autoimmune disease caused by antibodies targeted against protein-phospholipid complexes, which involves platelets, endothelium, thrombotic factors, prostacyclins, antithrombin, and proteins C and S. Antibodies interfere with anticoagulant factors, which leads to a hypercoagulable state. Among the most frequent clinical manifestations of APS are: systemic thrombosis, thrombocytopenia and recurrent fetal loss, being unusual to find ocular vascular occlusion (OVO) as a first manifestation. Method: Retrospective review of 3 cases of APS diagnosed between 1998 and 2001, in which OVO was the first manifestation. Diagnosis was made measuring anticardiolipin antibodies (IgM and IgG) and lupus anticoagulant titers. Results: Case 1: 25-year-old female with rheumatoid arthritis that presents with bilateral amaurosis fugax and afferent papillary defect in OD. Visual acuity (VA) was Hand Movement (HM) in OD and 20/100 in OS. Admission diagnosis: Central Retinal Artery Occlusion OU, APS and Lupus Erythematosus Systemicus. Case 2: 24-year-old male with high myopia and sudden onset of visual loss in OS. Admission diagnosis: Central Retinal Vein Occlusion OU, primary APS without systemic association. Case 3: 62-year-old male with chronic headache and bilateral amaurosis fugax with partial recovery to 20/80 in OS and HM in OD. Admission diagnosis: Choroidal occlusion OD, primary APS. 3 years later he develops subfoveal choroidal neovascularization in OS. All patients were evaluated by a rheumatologist, and received oral warfarin and prednisone in the acute period, improving clinically without systemic compromise. Conclusion: APS is associated with thrombotic phenomena which affect the ocular arterial and venous vasculature. It is important to discard APS in every patient (specially young ones) who presents with OVO or repeated amaurosis fugax episodes, due to its prevalence, potential consequences and effective response to treatment.

Keywords: 554 retina • 615 vascular occlusion/vascular occlusive disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.